Novogenia Launches Expanded MGT Plus Methylation Test in U.S. with 10X Health

Munich-based healthcare company Novogenia AG (ticker symbol: 7V0, formerly Darwin AG) has announced the U.S. launch of its new MGT Plus methylation test, expanding its collaboration with U.S. partner 10X Health. The test analyzes 27 genes across six interconnected biological pathways, including energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This broader scope provides a more comprehensive picture of methylation processes compared to commercially available tests that analyze only a limited number of genes. Dr. Daniel Wallerstorfer, CEO of Novogenia, emphasized that the expanded analysis enables deeper insights into genetic factors and supports more personalized prevention and health strategies. The launch taps into the rapidly growing direct-to-consumer genetic testing market, which reached approximately $4.7 billion in 2025 and is projected to exceed $16.0 billion by 2033, with North America accounting for about 50% of the global market volume. Novogenia's commitment to making scientific innovations accessible internationally is underscored by this partnership, as detailed in the original release on NEWMEDIAWIRE. The company operates its own laboratory for genetic analyses and partners with healthcare professionals to optimize patient care based on genetic predispositions. For more information, visit Novogenia AG.

The MGT Plus test represents a significant advancement in methylation analysis, offering a more holistic view of critical biochemical processes. Methylation influences the function of vitamins and neurotransmitters, impacting overall health and well-being. By covering 27 genes, the test provides insights that can guide personalized prevention and health strategies, potentially improving outcomes for individuals seeking to optimize their health. This launch is particularly timely given the growing interest in personalized health information and preventive care. The collaboration between Novogenia and 10X Health aims to bring these advanced genetic insights to a broader audience, strengthening their international product pipeline. As the genetic testing market expands, particularly in North America, Novogenia's innovative approach positions it well to capitalize on this trend, offering consumers and healthcare providers a more comprehensive tool for understanding and managing health at the genetic level.